Common side effects your patients may experience1

Set the right expectations with your patients: important information on Trulicity® side effects

Set the right expectations with your patients: important information on Trulicity® side effects

Of the most common adverse reactions in clinical studies while taking Trulicity, the majority were gastrointestinal (GI) and were usually reported as mild to moderate.1

  • In placebo-controlled trials, GI side effects among patients receiving Trulicity 0.75 mg, 1.5 mg, and placebo were 32%, 41%, and 21%, respectively
  • Of patients who reported GI side effects, 58% and 48% reported them as mild and 35% and 42% reported them as moderate at the Trulicity 0.75 mg and 1.5 mg doses, respectively
  • Discontinuation rates due to GI adverse reactions were 1.3% for 0.75 mg, 3.5% for 1.5 mg and 0.2% for placebo

There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis, in patients treated with GLP-1 receptor agonists. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In patients with renal impairment, use caution when initiating or escalating doses of Trulicity and monitor renal function in patients experiencing severe adverse gastrointestinal reactions.

Use of Trulicity may be associated with gastrointestinal adverse reactions, sometimes severe. Trulicity has not been studied in and is not recommended for patients with a history of severe gastrointestinal disease (eg, severe gastroparesis).

Adverse reactions in placebo-controlled studies through 26 weeks, reported in ≥5% of patients treated with Trulicity1

Adverse reactions chart

*Adverse reaction term represents >1 preferred MedDRA terms, clustered under a single, common term. Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.

The risk of hypoglycemia is increased when Trulicity is used in combination with insulin secretagogues (eg, sulfonylureas) or insulin. Patients may require a lower dose of sulfonylurea or insulin to reduce the risk of hypoglycemia.


  1. Trulicity [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; 2015.